We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
News

PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company

PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
News

PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PrimeraDx announced that it has entered into a multi-year relationship with Eli Lilly and Company to develop diagnostic products in support of multiple clinical development programs for novel therapeutics.  Under the terms of this agreement, the two companies will collaborate to develop innovative multiplex assays on PrimeraDx’s clinical platform, the ICEPlex® System.

Dr. Matt McManus, President and CEO of PrimeraDx said, “This relationship really moves our company forward in achieving our goals of bringing personalized medicine to the clinic and being the leader in the high-value companion diagnostics space. These programs are a tremendous validation of our technology and its utility in the development of complex tests to better diagnose and treat patients.  We are very excited about collaborating with Lilly on these important programs.”

“We have great expectations of our collaboration with PrimeraDx,” said Dr. Andrew Schade, Senior Director, Clinical Diagnostics Laboratory at Lilly.  “The unique ability of the ICEPlex System to combine multiple DNA and RNA biomarkers into a single multiplex assay could prove invaluable in our drive to develop companion diagnostics for crucial assets in our clinical pipeline.

“Our early focus will be in oncology, but as with all of our early research, we will apply learnings across therapeutic areas,” added Schade.

Advertisement